The Effects of Banha-sasim-tang on Dyspeptic Symptoms and Gastric Motility in Cases of Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled, and Two-Center Trial

Jae-Woo Park, Seok-Jae Ko, Gajin Han, Inkwon Yeo, Bongha Ryu, Jinsung Kim, Jae-Woo Park, Seok-Jae Ko, Gajin Han, Inkwon Yeo, Bongha Ryu, Jinsung Kim

Abstract

Introduction. Functional dyspepsia (FD) is highly prevalent, and no standard treatments exist for this condition. Herbal prescriptions are widely used to treat FD. In traditional Korean medicine, Banha-sasim-tang (BST) is a famous herbal prescription for dyspepsia. This study aimed to evaluate the efficacy of BST and to examine the relationship between gastric slow waves and dyspeptic symptoms. Materials and Methods. In total, 100 FD patients were recruited; BST or placebo was administered for 6 weeks. The gastrointestinal symptom scale, FD-related quality of life scale, and frequency or power variables regarding gastric slow waves were measured at 0, 6, and 14 weeks. Results. There were no significant differences in the overall dyspeptic symptoms or quality of life between the BST and placebo groups. However, early satiety was significantly improved in the BST group (P = 0.009, at 6 weeks by intention-to-treat analysis). Abnormal gastric dysrhythmias and power ratios were also significantly improved by BST. Conclusion. BST had no significant effects on FD. However, early satiety appeared to improve after BST administration. Electrogastrography may be a useful technique for assessing changes in gastric motility dysfunction after interventions for FD. Further investigation focused on specific symptoms or subtypes of FD is required.

Figures

Figure 1
Figure 1
Flow chart of the trial.
Figure 2
Figure 2
Changes in main outcomes of the trial. (a) Changes in the total scores of gastrointestinal symptom (GIS) scale between BST and placebo groups during the whole trial. (b) Changes in visual analogue scale (VAS) for overall symptoms between BST and placebo groups during the whole trial. (c) Changes in the total scores of functional dyspepsia-related quality of life (FD-QoL) between BST and placebo groups during the whole trial. BST: Banha-sasim-tang. F/U: follow-up period.

References

    1. von Arnim U, Peitz U, Vinson B, Gundermann K, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. American Journal of Gastroenterology. 2007;102(6):1268–1275.
    1. El-Serag HB, Talley NJ. Systematic review: the prevalence and clinical course of functional dyspepsia. Alimentary Pharmacology and Therapeutics. 2004;19(6):643–654.
    1. Lee JS. The guideline for diagnosis of functional dyspepsia. Korean Journal of Neuroenterology and Motility. 2005;11(3):18–24.
    1. Talley NJ, Meineche-Schmidt V, Paré P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies) Alimentary Pharmacology and Therapeutics. 1998;12(11):1055–1065.
    1. Holtmann G, Gschossmann J, Mayr P, Talley NJ. A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. Alimentary Pharmacology and Therapeutics. 2002;16(9):1641–1648.
    1. Froehlich F, Gonvers JJ, Wietlisbach V, et al. Eradication in Dyspepsia (ERADYS) Study Group: Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. American Journal of Gastroenterology. 2001;96(8):2329–2336.
    1. Zheng H, Tian X, Li Y, et al. Acupuncture as a treatment for functional dyspepsia: design and methods of a randomized controlled trial. Trials. 2009;10(article 75)
    1. Oikawa T, Ito G, Hoshino T, Koyama H, Hanawa T. Hangekobokuto (Banxia-houpo-tang), a Kampo medicine that treats functional dyspepsia. Evidence-Based Complementary and Alternative Medicine. 2009;6(3):375–378.
    1. Kupcinskas L, Lafolie P, Lignell Å, et al. Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: a prospective, randomized, double blind, and placebo-controlled study. Phytomedicine. 2008;15(6-7):391–399.
    1. World Health Organization. WHO International Standard Terminologies on Traditional Medicine in the Western Pacific Region. WHO Library Cataloguing in Publication Data; 2007.
    1. Naito T, Itoh H, Yasunaga F, Takeyama M. Hange-shashin-to raises levels of somatostatin, motilin, and gastrin in the plasma of healthy subjects. Biological and Pharmaceutical Bulletin. 2002;25(3):327–331.
    1. Naito T, Itoh H, Takeyama M. Some gastrointestinal function regulatory Kampo medicines have modulatory effects on human plasma adrenocorticotropic hormone and cortisol levels with continual stress exposure. Biological and Pharmaceutical Bulletin. 2003;26(1):101–104.
    1. Naito T, Itoh H, Takeyama M. Comparison of the effects of Hange-shashin-to and Rikkunshi-to on human plasma calcitonin gene-related peptide and substance P levels. Biological and Pharmaceutical Bulletin. 2003;26(8):1104–1107.
    1. Zhao L, Zhang S, Wang Z, et al. Efficacy of modified Ban Xia Xie Xin decoction on functional dyspepsia of cold and heat in complexity syndrome: a randomized controlled trial. Evidence-Based Complementary and Alternative Medicine. 2013;2013:8 pages.812143
    1. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006;130(5):1466–1479.
    1. Adam B, Liebregts T, Saadat-Gilani K, Vinson B, Holtmann G. Validation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia. Alimentary Pharmacology and Therapeutics. 2005;22(4):357–363.
    1. Park J, Ryu B, Yeo I, et al. Banha-sasim-tang as an herbal formula for the treatment of functional dyspepsia: a randomized, double-blind, placebo-controlled, two-center trial. Trials. 2010;11(article 83)
    1. Lee E, Hahm K, Lee JH, et al. Development and validation of a functional dyspepsia-related quality of life (FD-QOL) scale in South Korea. Journal of Gastroenterology and Hepatology. 2006;21(1):268–274.
    1. Sha W, Pasricha PJ, Chen JDZ. Rhythmic and spatial abnormalities of gastric slow waves in patients with functional dyspepsia. Journal of Clinical Gastroenterology. 2009;43(2):123–129.
    1. Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J. Treatment of functional dyspepsia with a herbal preparation: a double-blind, randomized, placebo-controlled, multicenter trial. Digestion. 2004;69(1):45–52.
    1. Talley NJ, Locke GR, Lahr BD, et al. Predictors of the placebo response in functional dyspepsia. Alimentary Pharmacology and Therapeutics. 2006;23(7):923–936.
    1. Parkman HP, Hasler WL, Barnett JL, Eaker EY. Electrogastrography: a document prepared by the gastric section of the American Motility Society Clinical GI Motility Testing Task Force. Neurogastroenterology and Motility. 2003;15(2):89–102.
    1. Sha W, Pasricha PJ, Chen JDZ. Correlations among electrogastrogram, gastric dysmotility, and duodenal dysmotility in patients with functional dyspepsia. Journal of Clinical Gastroenterology. 2009;43(8):716–722.
    1. van der Voort IR, Osmanoglou E, Seybold M, et al. Electrogastrography as a diagnostic tool for delayed gastric emptying in functional dyspepsia and irritable bowel syndrome. Neurogastroenterology and Motility. 2003;15(5):467–473.
    1. Verhagen MAMT, van Schelven LJ, Samsom M, Smout AJPM. Pitfalls in the analysis of electrogastrographic recordings. Gastroenterology. 1999;117(2):453–460.
    1. Familoni BO, Bowes KL, Kingma YJ, Cote KR. Can transcutaneous recordings detect gastric electrical abnormalities? Gut. 1991;32(2):141–146.
    1. Chen JDZ, Schirmer BD, McCallum RW. Serosal and cutaneous recordings of gastric myoelectrical activity in patients with gastroparesis. American Journal of Physiology. 1994;266(1):G90–G98.
    1. Yin J, Chen JD. Electrogatrography: methodology, validation and applications. Journal of Neurogastroenterology and Motility. 2013;19(1):5–17.
    1. Simonian HP, Panganamamula K, Parkman HP, et al. Multichannel Electrogastrography (EGG) in normal subjects: a multicenter study. Digestive Diseases and Sciences. 2004;49(4):594–601.
    1. Enck P, Klosterhalfen S. The placebo response in functional bowel disorders: perspectives and putative mechanisms. Neurogastroenterology and Motility. 2005;17(3):325–331.
    1. Thompson WG. Placebos: a review of the placebo response. American Journal of Gastroenterology. 2000;95(7):1637–1643.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj